A recurrent endometrial stromal sarcoma harbors the novel fusion JAZF1-BCORL1

Allison J Allen; Siraj M Ali; Kyle Gowen; Julia A Elvin; Tanja Pejovic

doi:10.1016/j.gore.2017.03.002

A recurrent endometrial stromal sarcoma harbors the novel fusion JAZF1-BCORL1

Gynecol Oncol Rep. 2017 Mar 8:20:51-53. doi: 10.1016/j.gore.2017.03.002. eCollection 2017 May.

Authors

Allison J Allen¹, Siraj M Ali², Kyle Gowen², Julia A Elvin², Tanja Pejovic¹

Affiliations

¹ Department of Obstetrics and Gynecology and the Knight Cancer Institute, Oregon Health & Science University, Portland, OR, United States.
² Foundation Medicine, Inc., Cambridge, MA, United States.

Abstract

•Genomic alterations may improve diagnostic certainty and subsequent treatment of endometrial stromal sarcoma.•Novel JAZF1-BCORL1 mutation was identified.•Targeted therapeutics to down-stream targets may improve survival benefit in these patients.

Keywords: Chromatin; Endometrial stromal sarcoma; JAZF1; Polycomb.

Publication types

Case Reports